| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| R M Hagan, B J Jones, C C Jordan, M B Tyer. Effect of 5-HT3 receptor antagonists on responses to selective activation of mesolimbic dopaminergic pathways in the rat. British journal of pharmacology. vol 99. issue 2. 1990-05-30. PMID:1691672. |
these results are in agreement with the proposed facilitatory role of 5-ht3 receptor activation on mesolimbic dopaminergic transmission, and suggest that 5-ht3 antagonists may have important therapeutic indications for the treatment of cns disorders in which mesolimbic dopamine systems are perturbed. |
1990-05-30 |
2023-08-11 |
rat |
| V Simonneaux, L C Murrin, M Ebad. Characterization of D1 dopamine receptors in the bovine pineal gland with [3H]SCH 23390. The Journal of pharmacology and experimental therapeutics. vol 253. issue 1. 1990-05-30. PMID:2139469. |
dopaminergic receptor agonists and antagonists inhibited [3h]sch 23390 binding in a concentration-dependent and stereoselective fashion, demonstrating a pharmacology characteristic of d1 dopamine receptors. |
1990-05-30 |
2023-08-11 |
cattle |
| M C Bohn, M Kanuick. Bilateral recovery of striatal dopamine after unilateral adrenal grafting into the striatum of the 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine (2'CH3-MPTP)-treated mouse. Journal of neuroscience research. vol 25. issue 3. 1990-05-24. PMID:1969970. |
in striking contrast to the unilateral recovery of the dopaminergic fibers, striatal dopamine levels were increased bilaterally in all tissue grafted mice. |
1990-05-24 |
2023-08-11 |
mouse |
| A R Crossma. A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. Movement disorders : official journal of the Movement Disorder Society. vol 5. issue 2. 1990-05-24. PMID:1970120. |
in levodopa- or dopamine agonist-induced dyskinesia, (c) the site of action of dopaminergic agents in causing chorea is the putamen. |
1990-05-24 |
2023-08-11 |
human |
| P Barone, S A Parashos, V Palma, C Marin, G Campanella, T N Chas. Dopamine D1 receptor modulation of pilocarpine-induced convulsions. Neuroscience. vol 34. issue 1. 1990-05-21. PMID:2139189. |
the contribution of dopaminergic mechanisms to the generalization of epileptic activity was studied in rats given pilocarpine after pretreatment with selective dopamine agonists. |
1990-05-21 |
2023-08-11 |
rat |
| J J Robert, M Orosco, C Rouch, Y Cohen, C Jacquo. Opposite dopaminergic activity in lateral and median hypothalamic nuclei in relation to the feeding effect of D-Ser2-Leu-Enk-Thr6 (DSLET). Brain research. vol 510. issue 1. 1990-05-21. PMID:2322848. |
the decreased dopaminergic activity in the lh would appear to be the most specifically related to the behavioural effect given the known role of dopamine in this region. |
1990-05-21 |
2023-08-11 |
rat |
| R Kuczenski, D S Segal, L D Manle. Apomorphine does not alter amphetamine-induced dopamine release measured in striatal dialysates. Journal of neurochemistry. vol 54. issue 5. 1990-05-18. PMID:2324735. |
the present experiments were designed to test the extent to which amphetamine-induced dopamine release is dependent on impulse flow and autoreceptor function in dopaminergic neurons. |
1990-05-18 |
2023-08-11 |
rat |
| R Kuczenski, D S Segal, L D Manle. Apomorphine does not alter amphetamine-induced dopamine release measured in striatal dialysates. Journal of neurochemistry. vol 54. issue 5. 1990-05-18. PMID:2324735. |
rats were pretreated with a low dose of apomorphine (0.05 mg/kg) to inhibit dopamine neuronal activity, and the striatal dopaminergic response to amphetamine (0.5 mg/kg) was assessed by in vivo dialysis in freely moving animals. |
1990-05-18 |
2023-08-11 |
rat |
| J M Cedarbau. Pharmacokinetic and pharmacodynamic considerations in management of motor response fluctuations in Parkinson's disease. Neurologic clinics. vol 8. issue 1. 1990-05-09. PMID:2181267. |
therapeutic approaches aimed at stabilizing brain dopaminergic activity include the use of slowly releasing galenic formulations of levodopa, synthetic dopamine agonists of long-lasting biologic activity, and drugs such as deprenyl that act as "dopamine extenders." |
1990-05-09 |
2023-08-11 |
Not clear |
| A Chagraoui, M Vasse, P Protai. Interaction of amineptine with agents modifying dopaminergic transmission. Clinical neuropharmacology. vol 12 Suppl 2. 1990-05-08. PMID:2576526. |
these data indicate that the stimulation of dopamine receptors induced by amineptine depends to a large degree on the dopamine released from the vesicular stores by the firing rate of dopaminergic neurons. |
1990-05-08 |
2023-08-11 |
mouse |
| T Nagats. [The search for endogenous or exogenous MPTP-like substances]. Rinsho shinkeigaku = Clinical neurology. vol 29. issue 12. 1990-05-04. PMID:2517047. |
like mptp, tiq inhibits tyrosine hydroxylase and nadph ubiquinone oxidoreductase to reduce dopamine and atp in the nigrostriatal dopaminergic neurons. |
1990-05-04 |
2023-08-11 |
human |
| B Dean, J Kulkarni, D L Copolo. Validation of a method to measure the uptake of [3H]dopamine by human platelets. Clinica chimica acta; international journal of clinical chemistry. vol 187. issue 1. 1990-05-02. PMID:2317927. |
dopamine uptake by prp may be useful in the study of diseases with altered dopaminergic activity in the cns. |
1990-05-02 |
2023-08-11 |
human |
| P J Williams, B A MacVicar, Q J Pittma. Synaptic modulation by dopamine of calcium currents in rat pars intermedia. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 10. issue 3. 1990-04-30. PMID:2181078. |
this possibility was tested by examining the effects of exogenously applied dopaminergic agonists or synaptically released dopamine upon ca2+ currents recorded under single electrode voltage clamp in intact rat pars intermedia in vitro. |
1990-04-30 |
2023-08-11 |
rat |
| W D Bowen, E L Moses, P J Tolentino, J M Walke. Metabolites of haloperidol display preferential activity at sigma receptors compared to dopamine D-2 receptors. European journal of pharmacology. vol 177. issue 3. 1990-04-26. PMID:2155804. |
these findings suggest that administration of haloperidol results initially in effects mediated through both dopamine and sigma receptors, but as metabolism proceeds the sigma actions would be expected to decline at a significantly slower rate than the dopaminergic actions. |
1990-04-26 |
2023-08-11 |
rat |
| C Missale, C Lombardi, R De Cotiis, M Memo, M O Carruba, P F Span. Dopaminergic receptor mechanisms modulating the renin-angiotensin system and aldosterone secretion: an overview. Journal of cardiovascular pharmacology. vol 14 Suppl 8. 1990-04-25. PMID:2483440. |
dopamine, which has no significant effects on ang ii-induced aldosterone secretion in sodium-replete subjects, inhibits the hormonal response to ang ii infusion in sodium-depleted normal subjects, suggesting that the sodium balance state may be an important factor in the dopaminergic mechanisms controlling aldosterone secretion. |
1990-04-25 |
2023-08-11 |
human |
| C Missale, M Metra, S Sigala, M Memo, L Dei Cas, P F Span. Inhibition of aldosterone secretion by dopamine, ibopamine, and dihydroergotoxine in patients with congestive heart failure. Journal of cardiovascular pharmacology. vol 14 Suppl 8. 1990-04-25. PMID:2483443. |
in this study we evaluated the effects of dopamine and the dopaminergic agonists ibopamine and dihydroergotoxine on aldosterone secretion and plasma renin activity in 13 patients with chronic heart failure. |
1990-04-25 |
2023-08-11 |
Not clear |
| C Missale, M Metra, S Sigala, M Memo, L Dei Cas, P F Span. Inhibition of aldosterone secretion by dopamine, ibopamine, and dihydroergotoxine in patients with congestive heart failure. Journal of cardiovascular pharmacology. vol 14 Suppl 8. 1990-04-25. PMID:2483443. |
two groups of patients were noted: one responding to dopaminergic drugs with a decrease in plasma aldosterone and the other without dopamine agonist-related aldosterone suppression. |
1990-04-25 |
2023-08-11 |
Not clear |
| W C Hall, R L Talbert, L Ereshefsk. Cocaine abuse and its treatment. Pharmacotherapy. vol 10. issue 1. 1990-04-24. PMID:2179901. |
dopaminergic systems are the principal sites of reward and participate in abstinence symptomatology, putatively through depletion of dopamine and changes in receptor sensitivity and responsiveness. |
1990-04-24 |
2023-08-11 |
Not clear |
| A Dearry, J L Edelman, S Miller, B Burnsid. Dopamine induces light-adaptive retinomotor movements in bullfrog cones via D2 receptors and in retinal pigment epithelium via D1 receptors. Journal of neurochemistry. vol 54. issue 4. 1990-04-20. PMID:2156019. |
we previously reported that 3,4-dihydroxyphenylethylamine (dopamine) mimicked the effect of light on these movements in photo-receptors and rpe cells of green sunfish, lepomis cyanellus, by interacting with d2 dopaminergic receptors. |
1990-04-20 |
2023-08-11 |
Not clear |
| A Dearry, J L Edelman, S Miller, B Burnsid. Dopamine induces light-adaptive retinomotor movements in bullfrog cones via D2 receptors and in retinal pigment epithelium via D1 receptors. Journal of neurochemistry. vol 54. issue 4. 1990-04-20. PMID:2156019. |
these results suggest that induction of cone contraction by dopamine is mediated by d2 dopaminergic receptors and that cone adenylate cyclase activity is inhibited. |
1990-04-20 |
2023-08-11 |
Not clear |